Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
The blood test identifies biomarkers that could make patients eligible for targeted therapies.
Precision medicine matches patients with the treatments most likely to work for them.
FDA grants regular approval to Alecensa for anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer.
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.